Our team will continue to expand the sample size to determine the clinical efficacy of furmonertinib as first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.